Business & Finance
AstraZeneca and European Commission reach vaccine supply agreement, ending litigation
6 September 2021 -

UK-based pharmaceutical company AstraZeneca announced on Friday that it has reached an agreement with the European Commission that ends legal proceedings over the execution of the Advance Purchase Agreement for the delivery of the COVID-19 vaccine Vaxzevria (ChAdOx1-S [Recombinant]).

Under the agreement, AstraZeneca commits to deliver 60 million doses of the vaccine by the end of the third quarter 2021, 75 million by the end of the fourth quarter 2021 and 65 million by the end of the first quarter 2022. Member States will be provided with regular delivery schedules, and capped rebates will apply in the event of any delayed doses.

Ruud Dobber, executive vice president, BioPharmaceuticals Business Unit, AstraZeneca, said: 'I'm very pleased that we have been able to reach a common understanding which allows us to move forward and work in collaboration with the European Commission to help overcome the pandemic. We are fully committed to manufacture Vaxzevria for Europe following the release for supply of more than 140 million doses to date at no profit. We are also looking forward to working with the European Commission in a joint effort to further support COVAX.'

Legal proceedings by the European Commission against AstraZeneca were initiated in Brussels on 21 April 2021. Court hearings were scheduled at end of September 2021.

AstraZeneca says that to date it and its partners have supplied more than 1.1 billion doses of vaccine to over 170 countries; approximately two thirds have gone to low- and lower-middle-income countries.